Latest Headlines

Latest Headlines

Roche's Bina wins competition for cancer-detecting algorithms

Bina's algorithm for the detection of small insertions and deletions placed first in its class in the DREAM Mutation Calling Challenge, while its somatic single nucleotide variant tool took second in its subcategory.

Roche-partnered Oryzon plans Madrid IPO as launchpad to Nasdaq

Oryzon Genomics has joined the wave of European biotechs to file for an IPO on their home continent. But the Roche-partnered epigenetics specialist is doing things differently, first by going public in the biotech backwater of the Madrid stock exchange and then by using this listing as a launchpad for a Nasdaq IPO.

Roche preps for make-or-break MS data with eyes on a crowded space

Roche's in-development treatment for multiple sclerosis met its main efficacy goals in pair of Phase III trials, but the looming release of full study results will likely influence how well the drug can contend with top-selling products already on the market.

Boehringer's Ofev, chasing a Roche rival, wins backing from NICE

Boehringer Ingelheim and Roche's meds for idiopathic pulmonary fibrosis may have won FDA approval on the same day, but in Europe, BI's contender, Ofev, has been playing catch-up since snagging its regulatory green-light. On Friday, though, it got a boost from British cost watchdogs could help it out in that department.

Roche CEO: Despite China worries, emerging markets will continue to deliver growth

Roche CEO Severin Schwan isn't worried about the company's progress in emerging markets. While the helmsman acknowledged a slowdown in China and currency issues in Brazil, the company is still on track to post growth in the long term, Schwan said in an interview with Bloomberg.

Chugai and Roche get U.S. FDA priority review on alectinib

Japan's Chugai Pharmaceutical and Switzerland's Roche's and its Genentech unit received U.S. FDA acceptance for a new drug application of alectinib for ALK positive advanced non-small cell lung cancer in patients for whom crizotinib is no longer an option.

Roche CEO lashes out at U.K.'s 'stupid' move to stop paying for a dozen-plus cancer meds

The U.K.'s special cancer drugs fund gave the heave-ho to a slate of treatments, including Roche's cutting-edge breast cancer treatment Kadcyla and Celgene's Abraxane for pancreatic cancer. Drugmakers are hopping mad, cancer treatment charities are despairing--and the fund and some public officials are on the defensive.

Roche gets a 'breakthrough' at the FDA for a top PhIII development effort

Roche got a boost for one of its top late-stage prospects from the FDA today. The agency has handed out a breakthrough drug designation for its hemophilia A treatment ACE910 among patients with factor VIII inhibitors.

European pharma lobby says 'non' to French funding for off-label Avastin

The French government recently said "oui" to Roche's ($RHHBY) cancer drug Avastin as a cheap, off-label treatment for the blinding eye disease wet age-related macular degeneration (AMD), prompting a resounding "non" from the pharma industry, which is none-too-pleased with the country's latest move.

Roche shops around for sequencing tech with Lumora buy

Roche has been hot on the trail of sequencing deals this past year, snatching up companies to build out its genomic analysis offerings. In its latest move, the company is buying sequencing products from molecular diagnostics firm Lumora to support its burgeoning portfolio.